New product filings to FDA included stronger safety features and larger technological advances
Dedicated FDA staff guide companies during design of clinical trials
Pharma companies less likely to disclose critical drug information than public institutions
R&D outlays and patents alone don’t effectively measure corporate creativity
Sales forecasting improves markedly as firms participate in standard setting organizations
Backers like to offer suggestions to a not-quite-finished product
Researchers aim to help the agency, drug companies and patients better understand the complex authorization process
Field researchers constructed a model to subsidize essential goods for low-income communities in crisis, and profit in recovery